Karyopharm Therapeutics Inc

$ 6.190 <%= Resources.Global.txtUp %>
Updated 23/05/2019
Change % 1.48% Stock price increasing
Change 0.09 Stock price increasing
Volume 1,512,846
High $ 6.280
Low $ 5.800
Open $ 6.100
Prev close $ 6.100
# of shares 60.86M
Market cap 376.75M USD

Market closed
Karyopharm Therapeutics Inc
Market is closed, opens at 14:30
Price development Latest 1 week 1 month 3 months 6 months 1 year
  6.19 33.4% Stock price increasing 29.0% Stock price increasing 22.3% Stock price increasing -41.1% Stock price decreasing -65.0% Stock price decreasing
Powered by TradingView

News about Karyopharm Therapeutics Inc

  • English
  • Regulatory news

Company profile

Karyopharm Therapeutics Inc., is a clinical-stage pharmaceutical company focused on the discovery, development and subsequent commercialization of novel, first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. The company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. Karyopharm's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
25 May 2019 20:53:39
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190514.2 - EUROWEB7 - 2019-05-25 21:53:39 - 2019-05-25 20:53:39 - 1000 - Website: OKAY